Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 511 AL 525

Cancer and Alzheimer's disease inverse relationship: an age-associated diverging derailment of shared pathways

Lanni C, Masi M, Racchi M, Govoni S.

Mol Psychiatry. 2021 Jan;26(1):280-295. doi: 10.1038/s41380-020-0760-2. Epub 2020 May 7.

Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis

Plascencia-Villa G, Perry G.

Antioxid Redox Signal. 2021 Mar 10;34(8):591-610. doi: 10.1089/ars.2020.8134. Epub 2020 Jul 17.

From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology

Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML.

Med Res Rev. 2021 Sep;41(5):2606-2633. doi: 10.1002/med.21699. Epub 2020 Jun 19.

Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease

Shevtsova EF, Maltsev AV, Vinogradova DV, Shevtsov PN, Bachurin SO.

Med Res Rev. 2021 Mar;41(2):803-827. doi: 10.1002/med.21715. Epub 2020 Jul 20.

Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort

Abdeljalil AB, de Mauléon A, Baziard M, Vellas B, Lapeyre-Mestre M, Soto M.

J Am Med Dir Assoc. 2021 Feb;22(2):433-439. doi: 10.1016/j.jamda.2020.06.028. Epub 2020 Jul 28.

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Gadhave K, Kumar D, Uversky VN, Giri R.

Med Res Rev. 2021 Sep;41(5):2689-2745. doi: 10.1002/med.21719. Epub 2020 Aug 11.

Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases

Özdinler PH.

FEBS J. 2021 Mar;288(5):1457-1461. doi: 10.1111/febs.15529. Epub 2020 Sep 5.

Shared signaling pathways in Alzheimer's and metabolic disease may point to new treatment approaches

Suresh J, Khor IW, Kaur P, Heng HL, Torta F, Dawe GS, Tai ES, Tolwinski NS.

FEBS J. 2021 Jun;288(12):3855-3873. doi: 10.1111/febs.15540. Epub 2020 Sep 10.

Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery

Zameer S, Ali J, Vohora D, Najmi AK, Akhtar M.

J Drug Target. 2021 Feb;29(2):199-216. doi: 10.1080/1061186X.2020.1817041. Epub 2020 Sep 10.

Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets

Uddin MS, Al Mamun A, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM.

Mol Neurobiol. 2021 Jan;58(1):281-303. doi: 10.1007/s12035-020-02116-9. Epub 2020 Sep 15.

Tubulin modifying enzymes as target for the treatment of tau-related diseases

Rogowski K, Hached K, Crozet C, van der Laan S.

Pharmacol Ther. 2021 Feb;218:107681. doi: 10.1016/j.pharmthera.2020.107681. Epub 2020 Sep 19.

Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease

Bonfili L, Cecarini V, Gogoi O, Gong C, Cuccioloni M, Angeletti M, Rossi G, Eleuteri AM.

FEBS J. 2021 May;288(9):2836-2855. doi: 10.1111/febs.15571. Epub 2020 Oct 8.

Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)

Rombouts F, Kusakabe KI, Hsiao CC, Gijsen HJM.

Expert Opin Ther Pat. 2021 Jan;31(1):25-52. doi: 10.1080/13543776.2021.1832463. Epub 2020 Dec 17.

From bedside to battlefield: intersection of ketone body mechanisms in geroscience with military resilience

Stubbs BJ, Koutnik AP, Volek JS, Newman JC.

Geroscience. 2021 Jun;43(3):1071-1081. doi: 10.1007/s11357-020-00277-y. Epub 2020 Oct 2.

Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F.

Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias